Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blind, Placebo-controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)

NCT02895191 is registered in ClinicalTrials.gov with Techpool Bio-Pharma Co., Ltd. as lead sponsor.

NCT NCT02895191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02895191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blind, Placebo-controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)
Lead sponsor
Techpool Bio-Pharma Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2016
Completion date
December 31, 2019
Enrollment
60 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome